Is sarcoidosis related to metabolic syndrome and insulin resistance?

Basit Öğe Kaydı
dc.authoridyildiz gulhan, pinar/0000-0002-5347-2365
dc.authoridBalbay, Ege Gulec/0000-0002-1557-7019
dc.authorwosidyildiz gulhan, pinar/AAW-3004-2020
dc.authorwosidtemel, sahin/AAC-5750-2020
dc.authorwosidBalbay, Ege Gulec/V-5497-2017
dc.contributor.authorGulhan, Pinar Yildiz
dc.contributor.authorBalbay, Ege Gulec
dc.contributor.authorErcelik, Merve
dc.contributor.authorYildiz, Seyma
dc.contributor.authorYilmaz, Mehmet Alper
dc.date.accessioned2021-12-01T18:49:46Z
dc.date.available2021-12-01T18:49:46Z
dc.date.issued2020
dc.department[Belirlenecek]en_US
dc.description.abstractAim: To investigate the relationship between sarcoidosis and metabolic syndrome (MetS) and insulin resistance (IR). Method: In our study, 47 patients with sarcoidosis who applied to our outpatient clinic and 45 healthy individuals without chronic disease were included. All patients were evaluated for MetS according to the National Cholesterol Education Program's Adult Treatment Panel III (NCEP-ATP III) criteria. The presence of three of the five factors defined by ATP III for MetS was accepted as a diagnosis of MetS. IR is calculated using the HOMA-IR index. Results: The mean age of the 47 patients with sarcoidosis was 50.7 +/- 12.2 years and the mean age of the 45 control groups was 42.9 +/- 14.4 years. Almost 80% of the patients were diagnosed as stage 2 sarcoidosis. Distribution of the patients according to the use of steroid is; almost half of the patients (47%) received steroid previously or recently. Patients with sarcoidosis have a 7.66 relative risk for MetS, whereas they also have a 5.48 relative risk of insulin resistance development. Conclusion: This study shows that MetS is associated with increased sarcoidosis risk. MetS and IR diagnosis was higher in patients with sarcoidosis.en_US
dc.identifier.doi10.1080/13685538.2019.1631272
dc.identifier.endpage58en_US
dc.identifier.issn1368-5538
dc.identifier.issn1473-0790
dc.identifier.issue1en_US
dc.identifier.pmid31250684en_US
dc.identifier.scopus2-s2.0-85068216755en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage53en_US
dc.identifier.urihttps://doi.org/10.1080/13685538.2019.1631272
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10775
dc.identifier.volume23en_US
dc.identifier.wosWOS:000473823900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofAging Maleen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInsulin resistanceen_US
dc.subjectHOMA-IRen_US
dc.subjectmetabolic syndromeen_US
dc.subjectNCEP-ATP IIIen_US
dc.subjectsarcoidosisen_US
dc.subjectNecrosis-Factor-Alphaen_US
dc.subjectAdipose-Tissueen_US
dc.subjectMedical Progressen_US
dc.subjectObesityen_US
dc.subjectInflammationen_US
dc.subjectRisken_US
dc.subjectExpressionen_US
dc.subjectAutoimmunityen_US
dc.subjectAdiponectinen_US
dc.subjectAdipokinesen_US
dc.titleIs sarcoidosis related to metabolic syndrome and insulin resistance?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
10775.pdf
Boyut:
2.83 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu